Protective effect of Hypericum perforatum in zymosan-induced multiple organ dysfunction syndrome: Relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity

Nitric Oxide - Biology and Chemistry

Volumn 16, Issue 1, 2007, Pages 118-130

  Paola, Rosanna Di ^a   Mazzon, Emanuela ^a,b   Muià, Carmelo ^a   Crisafulli, Concetta ^a   Genovese, Tiziana ^a,b   Bella, Paolo Di ^b   Esposito, Emanuela ^c   Menegazzi, Marta ^d   Meli, Rosaria ^c   Suzuki, Hisanori ^d   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Antioxidant; Hypericum perforatum; Nitric oxide; Oxidative stress; Zymosan induced multiple organ failure

Indexed keywords

3 NITROTYROSINE; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOQUERCITRIN; LUTEOLIN; MALTODEXTRIN; METHANOL EXTRACTION RESIDUE; MYELOPEROXIDASE; MYRICETIN; NITRIC OXIDE; PEROXYNITRITE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); POLYSACCHARIDE; QUERCETIN; SODIUM CHLORIDE; TANNIN; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME RELEASE; HYPERICUM PERFORATUM; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; INTESTINE; INTESTINE INJURY; KIDNEY DYSFUNCTION; LUNG; LUNG INJURY; MALE; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCREAS INJURY; PERITONEUM EXUDATE; PERITONITIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAVENGING SYSTEM; SUSPENSION; TISSUE SECTION; WEIGHT REDUCTION;

ANIMALS; HYPERICUM; IMMUNOHISTOCHEMISTRY; INTESTINES; LUNG; MALE; MICE; MULTIPLE ORGAN FAILURE; NEUTROPHILS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PLANT EXTRACTS; ZYMOSAN;

HYPERICUM PERFORATUM;

EID: 33751503444     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2006.05.006     Document Type: Article

References (71)

1. Faist E.A., Baue E., and Dittmer. Multiple organ failure in poly-trauma patients. J. Trauma 23 (1983) 775-787
2. Shayevitz J.R., Miller C., Johnson K.J., and Rodriguez J.L. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 4 (1995) 389-396
3. Jansen M.J.J.M., Hendriks T., Vogels M.T.E., van der Meer J.W.M., and Goris R.J.A. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit. Care Med. 24 (1996) 1196-1202
4. El-Sokkary G.H., Reiter R.J., Cuzzocrea S., Caputi A.P., Hassanein A.-F., and Tan D.-X. Role of melatonin in reduction of lipid peroxidation and peroxynitrite formation in nonseptic shock induced by zymosan. Shock 12 (1999) 402-408
5. Jansen M.J.J.M., Hendriks T., Knapen M.F.C.M., van Kempen L.C.L.T., van der Meer J.W.M., and Goris R.J.A. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice. Crit. Care Med. 26 (1998) 1244-1250
6. Kirton O.C., and Civetta J.M. Ischemia-reperfusion injury in the critically ill: a progenitor of multiple organ failure. New Horizons 7 (1999) 87-95
7. Demling R., Nayak U., Ikegami K., and LaLonde C. Comparison between lung and liver peroxidation and mortality after zymosan peritonitis in the rats. Shock 2 (1994) 222-227
8. Van Bebber I.P.T., Boekholz K.F., Goris R.J.A., Schillings P.H., Dinges H.P., Bahrami S., Redl H., and Schlag G. Neutrophil function and lipid peroxidation in rat model of multiple organ failure. J. Surg. Res. 47 (1989) 471-475
9. Petit F., Bagby G.J., and Lang C.H. Tumor necrosis factor mediates zymosan induced increase in glucose flux and insulin resistance. Am. J. Physiol. 268 (1995) 219-228
10. Damas J., Remacle-Volon G., and Bourdon V. Platelet-activating factor and vascular effects of zymosan in rats. Eur. J. Pharmacol. 231 (1993) 231-236
11. Deitch E.A., Ma W.J., Ma L., Berg R.D., and Specian R.D. Protein malnutrition predisposes to inflammatory-induced gut-origin septic states. Ann. Surg. 221 (1990) 560-568
12. Kelly B.A., and Carchman R.A. The relationship between lysosomal enzyme release and protein phosphorylation in human monocytes stimulated by phorbol esters and opsonized zymosan. J. Biol. Chem. 262 (1987) 17404-17411
13. Daum T., and Rohrbach M.S. Zymosan induces selective release of arachidonic acid from rabbit alveolar macrophages via stimulation of a b-glucan receptor. FEBS Lett. 309 (1992) 119-122
14. Sanguedolce M.V., Capo C., Bongrand P., and Mege J.L. Zymosan-stimulated tumor necrosis factor-a production by human monocytes. Down-modulation by phorbol ester. J. Immunol. 148 (1992) 2229-2236
15. Cuzzocrea S., De Sarro G.B., Costantino G., Mazzon E., Laurà R., Ciriaco E., De Sarro A., and Caputi A.P. Role of interleukine-6 in a non-septic shock model induced by zymosan. Eur. Cytokine Net 10 (1999) 191-203
16. Cuzzocrea S., Mazzon E., Di Paola R., Genovese T., Serraino I., Dugo L., Cuzzocrea E., Fulia F., Caputi A.P., and Salvemini D. Protective effects of M40401, a selective superoxide dismutase mimetic, on zymosan-induced nonseptic shock. Crit. Care Med. 32 (2004) 157-167
17. Ward P.A., Till G.O., Kunkel R., and Beuchamp C. Evidence for role of hydroxyl radical complement and neutrophil-dependent tissue injury. J. Clin. Invest. 72 (1983) 789-801
18. Fantone J.C., and Ward P.A. A review: role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am. J. Pathol. 107 (1982) 395-418
19. Yu J.H., Lim J.W., Namkung W., Kim H., and Kim K.H. Suppression of cerulein-induced cytokine expression by antioxidants in pancreatic acinar cells. Lab Invest. 82 (2002) 1359-1368
20. Schwartz J.T., and Cupp M.J. St. John's wort. In: Cupp M.J. (Ed). Toxicology and Clinical Pharmacology of Herbal Products (2000), Humana Press, Totowa, NJ 67-78
21. Di Carlo G., Borrelli F., Ernst E., and Izzo AA. St. John's wort: prozac from the plant kingdom. Trends Pharmacol. Sci. 22 (2001) 292-297
22. Barnes J., Ahnderson L.A., and Phillipson J.D. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol. 53 (2001) 583-600
23. Kumar V., Singh P.N., and Bhattacharya S.K. Anti-inflammatory and analgesic activity of Indian Hypericum perforatum L. Indian J. Exp. Biol. 39 (2001) 339-343
24. Saija A., Scalese M., Lanza M., Marzullo D., Bonina F., and Castelli F. Flavonoids as antioxidant agents: importance of their interaction with biomembranes. Free Radic. Biol. Med. 19 (1995) 481-486
25. Abd El-Gawad H.M., and Khalifa A.E. Quercetin, coenzyme Q10, and l-canavanine as protective agents against lipid peroxidation and nitric oxide generation in endotoxin-induced shock in rat brain. Pharmacol. Res. 43 (2001) 257-263
26. Mattace Raso G., Pacilio M., Di Carlo G., Esposito E., Pinto L., and Meli R. In vivo and in vitro anti-inflammatory effect of echinacea purpurea and Hypericum perforatum. J. Pharm. Pharmacol. 54 (2002) 1379-1383
27. Menegazzi M., Di Paola R., Mazzon E., Muià C., Genovese T., Crisafulli C., Suzuki H., and Cuzzocrea S. Hypericum perforatum attenuates the development of carrageenan-induced lung injury in mice. Free Radic. Biol. Med. 40 (2006) 740-753
28. Dugo L., Chatterjee P.K., Mazzon E., McDonald M.C., Paola R.D., Fulia F., Caputi A.P., Thiemermann C., and Cuzzocrea S. The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat. Intensive Care Med. 28 (2002) 775-788
29. Mullane K.M., Kraemer R., and Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Meth. 14 (1985) 157-167
30. McMenamy RH., Birkhahn R., Oswald G., et al. Multiple systems organ failure: the basal state. J. Trauma 21 (1981) 99-114
31. Cerra FB. Hypermetabolism, organ failure, and metabolic support. Surgery 101 (1987) 1-14
32. Butterweck V., Christoffel V., Nahrstedt A., Petereit F., Spengler B., and Winterhoff H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci. 73 (2003) 627-639
33. Hunt E.J., Lester C.E., Lester E.A., and Tackett R.L. Effect of St. John's wort on free radical production. Life Sci. 69 (2001) 181-190
34. Sloley B.D., and Urichuk L.J. Chemical and pharmacological evaluation of Hypericum perforatum extracts. Acta Pharmacol. Sin. 21 (2000) 1145-1152
35. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 140-141 (2003) 105-112
36. Haddad J.J. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal. 14 (2002) 879-897
37. Schreck R., Rieber P., and Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10 (1991) 247-258
38. Genovese T., Mazzon E., Di Paola R., Muia C., Crisafulli C., Menegazzi M., Malleo G., Suzuki H., and Cuzzocrea S. Hypericum perforatum attenuates the development of cerulein-induced acute pancreatitis in mice. Shock 25 (2006) 161-167
39. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J. Biol. Chem 269 (1994) 4705-4708
40. Collart M.A., Bauerle P.A., and Vassalli P. Regulation of tumour necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and inducible forms of NF-κB. Mol. Cell Biol. 10 (1990) 1490-1506
41. Barnes P.J., and Karin M. Nuclear factor kB-a pivotal transcription factor in chronic inflammatory disease. N. Engl. J. Med. 336 (1997) 1066-1071
42. Bauerle P.A., and Henkel T. Function and activation of NF-κB in the immune system. Ann. Rev. Immunol. 2 (1994) 141-179
43. Posadas I., Terencio M.C., Guillen I., Ferrandiz M.L., Coloma J., Paya M., and Alcaraz M.J. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 98-106
44. Tanriverdi P., Yuskel B.C., Rasa K., Guler G., Iskit A.B., Guc M.O., and Korkmaz A. The effects of selective nitric oxide synthase blocker on survival, mesenteric blood flow and multiple organ failure induced by zymosan. J. Surg. Res. 124 (2005) 67-73
45. Beckman J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9 (1996) 836-844
46. Cuzzocrea S., Riley D.P., Caputi A.P., and Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 53 (2001) 135-159
47. Rubbo H., Radi R., Trujillo M., et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation, Formation of novel nitrogen-containing oxidised lipid derivatives. J. Biol. Chem. 269 (1994) 26066-26075
48. Graham A., Hogg N., Kalyanaraman B., et al. Peroxynitrite modification of low density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 330 (1993) 18-25
49. Lancaster J.R. Nitric oxide in cells. Am. Sci. 80 (1992) 248-255
50. Mainous M.R., Ertel W., and Chaudry I.H. The gut: A cytokine-generating organ in systemic inflammation?. Shock 4 (1995) 193-199
51. Cuzzocrea S., Filippelli A., Zingarelli B., et al. Role of nitric oxide in a non-septic shock model induced by zymosan in the rat. Shock 7 (1997) 351-358
52. Cuzzocrea S., Zingarelli B., Sautebin L., et al. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. Shock 4 (1997) 268-275
53. Cuzzocrea S., Zingarelli B., Calapai G., et al. Zymosan-activated plasma induces paw oedema by nitric oxide and prostaglandin production. Life Sci. 60 (1997) 215-220
54. Cuzzocrea S., Zingarelli B., Costantino G., and Caputi A.P. Protective effect of melatonin in a non-septic shock model induced by zymosan in the rat. J. Pineal Res. 25 (1998) 24-33
55. Cuzzocrea S., Costantino G., Mazzon E., De Sarro A., and Caputi A.P. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in zymosan-induced shock. Br. J. Pharmacol. 128 (1999) 1241-1251
56. Cuzzocrea S., Rossi A., Pisano B., Di Paola R., Genovese T., Patel N.S., Cuzzocrea E., Ianaro A., Sautebin L., Fulia F., Chatterjee P.K., Caputi A.P., and Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med. 29 (2003) 2016-2025
57. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., and Van Der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391 (1998) 393-397
58. Marzocco S., Di Paola R., Genovese T., Sorrentino R., Britti D., Scollo G., Pinto A., Cuzzocrea S., and Autore G. Methylguanidine reduces the development of non septic shock induced by zymosan in mice. Life Sci. 75 (2004) 1417-1433
59. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., and Szabó C. Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in carrageenan-induced models of local inflammation. Eur. J. Pharmacol. 342 (1998) 67-76
60. Cuzzocrea S., Zingarelli B., Gilard E., Hake P., Salzman A.L., and Szabò C. Anti-inflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger in carrageenan-induced models of inflammation. Free Radic. Biol. Med. 24 (1998) 450-459
61. Szabó C., Lim L.H.K., Cuzzocrea S., Getting S.J., Zingarelli .B., Flower R.J., Salzman A.L., and Perretti M. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J. Exp. Med. 186 (1997) 1041-1049
62. Szabò C., Virag L., Cuzzocrea S., Scott G.S., Hake P., O'connor M., Zingarelli B., Ma Y., Hirsch R., Boiovin G.P., Salzman A.L., and Kun E. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc. Natl. Acad. Sci. USA 95 (1998) 3867-3872
63. Dahlen S.E. Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. Clin. Exp. Allergy 5 (1998) 141-146
64. Goulet J.L., Byrum R.S., Key M.L., Nguyen M., Wagoner V.A., and Koller BH. Genetic factors determine the contribution of leukotrienes to acute inflammatory responses. J. Immunol. 164 (2000) 4899-4907
65. Byrum R.S., Goulet J.L., Snouwaert J.N., Griffiths R.J., and Koller B.H. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J. Immunol. 163 (1999) 6810-6819
66. Gardinali M., Borrelli E., Chiara O., Lundberg C., Padalino P., Conciato L., Cafaro C., Lazzi S., Luzi P., Giomarelli P.P., and Agostani A. Inhibition of CD11-CD18 complex prevents acute lung injury and reduces mortality after peritonitis in rabbits. Am. J. Respir. Crit. Care Med. 161 (2000) 1022-1029
67. Swartz D.E., Seely A.J., Ferri L., Giannias B., and Christou N.V. Decreased systemic polymorphonuclear neutrophil (PMN) rolling without increased PMN adhesion in peritonitis at remote sites. Arch. Surg. 135 (2000) 959-966
68. Heller A.R., Fiedler F., Braun P., Stehr S.N., Bodeker H., and Koch T. Clusterin protects the lung from leukocyte-induced injury. Shock 20 (2003) 166-170
69. Tsujimoto H., Ono S., Mochizuki H., Aosasa S., Majima T., Ueno C., and Matsumoto A. Role of macrophage inflammatory protein 2 in acute lung injury in murine peritonitis. J. Surg. Res. 103 (2002) 61-67
70. P.S. Grutkoski, C.T. Graeber, A. Ayala, H.H. Simms, (2002) Paracrine suppression of apoptosis by cytokine-stimulated neutrophils involves divergent regulation of NF-kappaB, Bcl-X(L), and Bax, Shock 17 (1992) 47-54.
71. Cuzzocrea S., Mazzon E., Dugo L., Barbera A., Centorrino T., Ciccolo A., Fonti M.T., and Caputi A.P. Inducible nitric oxide synthase knock out mice exhibit a resistance to multiple organ failure induced by zymosan. Shock 16 (2001) 51-58